Neurocrine Biosciences Management
Management criteria checks 4/4
Neurocrine Biosciences' CEO is Kyle Gano, appointed in Jan 2011, has a tenure of 13.92 years. total yearly compensation is $5.99M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $18.33M. The average tenure of the management team and the board of directors is 7 years and 9.2 years respectively.
Key information
Kyle Gano
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 10.1% |
| CEO tenure | 13.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 7yrs |
| Board average tenure | 9.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$386m |
| Jun 30 2024 | n/a | n/a | US$339m |
| Mar 31 2024 | n/a | n/a | US$370m |
| Dec 31 2023 | US$6m | US$603k | US$250m |
| Sep 30 2023 | n/a | n/a | US$191m |
| Jun 30 2023 | n/a | n/a | US$176m |
| Mar 31 2023 | n/a | n/a | US$64m |
| Dec 31 2022 | US$5m | US$551k | US$155m |
| Sep 30 2022 | n/a | n/a | US$58m |
| Jun 30 2022 | n/a | n/a | US$12m |
| Mar 31 2022 | n/a | n/a | US$71m |
| Dec 31 2021 | US$6m | US$517k | US$90m |
| Sep 30 2021 | n/a | n/a | US$445m |
| Jun 30 2021 | n/a | n/a | US$365m |
| Mar 31 2021 | n/a | n/a | US$402m |
| Dec 31 2020 | US$7m | US$488k | US$407m |
| Sep 30 2020 | n/a | n/a | US$93m |
| Jun 30 2020 | n/a | n/a | US$205m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$443k | US$37m |
| Sep 30 2019 | n/a | n/a | US$21m |
| Jun 30 2019 | n/a | n/a | US$18m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | US$5m | US$403k | US$21m |
| Sep 30 2018 | n/a | n/a | US$10m |
| Jun 30 2018 | n/a | n/a | -US$52m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$2m | US$375k | -US$143m |
Compensation vs Market: Kyle's total compensation ($USD5.99M) is about average for companies of similar size in the UK market ($USD5.77M).
Compensation vs Earnings: Kyle's compensation has been consistent with company performance over the past year.
CEO
Kyle Gano (51 yo)
13.9yrs
Tenure
US$5,990,215
Compensation
Mr. Kyle W. Gano, Ph D., is CEO and Director at Neurocrine Biosciences, Inc since October 11, 2024. He was Chief Business Development and Strategy Officer at Neurocrine Biosciences, Inc. since 2020 until O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.9yrs | US$5.99m | 0.13% $ 18.3m | |
| Chief Financial Officer | 7.1yrs | US$6.06m | 0.031% $ 4.3m | |
| Chief Scientific Officer | 3.1yrs | US$7.22m | 0.015% $ 2.1m | |
| Chief Medical Officer | 6.9yrs | US$5.87m | 0.031% $ 4.2m | |
| Co-Founder of Neurocrine | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 10.2yrs | US$4.72m | 0.039% $ 5.4m | |
| Chief Human Resources Officer | 7.3yrs | no data | 0.018% $ 2.5m | |
| Chief Commercial Officer | 9.6yrs | US$5.81m | 0.040% $ 5.5m | |
| Chief Corporate Affairs Officer | 5.3yrs | no data | 0.00037% $ 50.7k | |
| Chief Regulatory Officer | 2.2yrs | no data | 0.0025% $ 340.0k | |
| Exclusive Consultant | 6.9yrs | US$3.10m | no data |
7.0yrs
Average Tenure
58yo
Average Age
Experienced Management: 0K6R's management team is seasoned and experienced (7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$5.99m | 0.13% $ 18.3m | |
| Independent Director | 1.4yrs | US$813.45k | 0% $ 0 | |
| Independent Director | 26.7yrs | US$492.04k | 0.031% $ 4.3m | |
| Independent Director | 25.7yrs | US$479.54k | 0.024% $ 3.3m | |
| Independent Chairman of the Board | 14.8yrs | US$495.04k | 0.037% $ 5.1m | |
| Independent Director | 31.8yrs | US$460.11k | 0.12% $ 16.1m | |
| Independent Director | 9.2yrs | US$479.54k | 0.0042% $ 569.0k | |
| Director | 16.9yrs | US$15.75m | 0.51% $ 69.7m | |
| Independent Director | 4.8yrs | US$497.11k | 0.00098% $ 134.4k | |
| Independent Director | 5.3yrs | US$475.11k | 0.00098% $ 134.4k | |
| Independent Director | 3.7yrs | US$467.61k | 0.0021% $ 283.8k |
9.2yrs
Average Tenure
66yo
Average Age
Experienced Board: 0K6R's board of directors are considered experienced (9.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 11:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neurocrine Biosciences, Inc. is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |